Trial Profile
Pharmacokinetics of meropenem and tazocin in septic patients requiring slow efficiency dialysis (SLED) with haemodiafiltration (HDF).
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2019
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Sepsis
- Focus Pharmacokinetics
- 05 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Jul 2016 New trial record